Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ENZN reported fourth quarter 2003 operating EPS ended June 30 of $0.26, which met the Street consensus
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury